ArticleCureus2025
Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to evaluate Janus kinase (JAK) inhibitor discontinuation rates and reasons for discontinuation in patients with inflammatory arthritis at a UK tertiary centre.
methodsPatients prescribed JAK inhibitors (tofacitinib, baricitinib, upadacitinib, and filgotinib) from May 2018 to October 2023 were included in this study, and those who discontinued their JAK inhibitor were identified. Statistical tests were conducted to assess for associations between discontinuation reasons and patient baseline characteristics.
resultsOf 400 patients, 102 (25.5%) discontinued their JAK inhibitors. Primary inefficacy was the most common discontinuation reason, reported in 35/102 patients (34.3%), followed by side effects in 25/102 patients (24.5%). Discontinuation rates varied among the drugs, with tofacitinib (33/64; 51.6%) and baricitinib (57/243; 23.5%) having higher overall discontinuation rates, and upadacitinib and filgotinib showing higher early discontinuation.
conclusionJAK inhibitor discontinuation is primarily driven by inefficacy and side effects, with variations by drug. Further studies are needed to explore long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.